Modafinil
Actimodan contains the active substance modafinil.
Actimodan is indicated for the treatment of excessive daytime sleepiness associated with narcolepsy with or without cataplexy (loss of muscle tone).
Excessive daytime sleepiness is defined as difficulty maintaining wakefulness and increased risk of falling asleep in inappropriate situations.
Modafinil may be taken by adult patients with narcolepsy to maintain wakefulness. Narcolepsy is a disease that causes excessive daytime sleepiness and a tendency to fall asleep suddenly in inappropriate situations (sleep attacks). Taking modafinil may improve narcolepsy and reduce the likelihood of sleep attacks. Improvement may also be achieved by using other methods; information about these methods can be obtained from your doctor.
Before starting to take Actimodan, discuss it with your doctor or pharmacist:
Some patients taking modafinil have reported suicidal or aggressive thoughts or aggressive behavior. You should immediately inform your doctor if you experience depression, feelings of aggression or hostility towards others, suicidal thoughts, or other changes in your behavior (see section 4). You may ask a family member or close friend to pay attention to any signs of depression or other changes in your behavior.
This medicine may be addictiveduring long-term use. If it is necessary to use the medicine for a longer period, your doctor will regularly check if it is still the best medicine for you.
There have been reports of severe skin reactions such as severe rash, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) associated with modafinil.
If a rash occurs, you should stop taking Actimodan and not restart it, and immediately contact your doctor.
The medicine should not be used in children and adolescents under 18 years of age.
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take.
Modafinil may interact with some other medicines.
Your doctor may need to adjust the doses of the medicines you are taking.
This is especially important if you are taking any of the following medicines with Actimodan:
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant (or think you may be pregnant), you should not take Actimodan.
It is not known whether the medicine can harm the unborn child.
If you are breastfeeding, you should not take Actimodan. It is not known whether the medicine passes into breast milk.
A woman of childbearing potential should discuss with her doctor which contraceptive methods are appropriate for her during treatment with modafinil (and for 2 months after stopping treatment) or if she has any other concerns.
The medicine may cause blurred vision or dizziness. If you experience these symptoms or if you still feel very sleepy while taking this medicine, you should not drive or operate machinery.
Lactose monohydrate
If you have been told that you have an intolerance to some sugars, you should contact your doctor before taking the medicine.
Sodium
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means that it is essentially "sodium-free".
This medicine should always be taken exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
Adults
The usual dose of the medicine is 200 mg per day. This dose can be taken once a day (in the morning) or in two divided doses per day (100 mg in the morning and 100 mg at noon).
In some cases, your doctor may decide to increase the daily dose to 400 mg in one or two divided doses.
Elderly patients (over 65 years)
The usual dose of the medicine is 100 mg per day.
Patients with liver function disorders
The usual dose of the medicine is 100 mg per day.
Your doctor will regularly review your treatment to ensure it is suitable for you.
The tablets should be swallowed whole with water.
If you have taken more than the recommended dose of the medicine, you should immediately contact the nearest hospital or inform your doctor.
You should take this leaflet and any remaining tablets with you.
Overdose symptoms may occur: insomnia, central nervous system symptoms such as restlessness, disorientation, confusion, mental excitement, and hallucinations; gastrointestinal symptoms such as nausea and diarrhea, and cardiovascular symptoms such as tachycardia, bradycardia, hypertension, and chest pain.
If you miss a dose, you should take the next dose at the usual time. Do not take a double dose to make up for the missed dose.
If you have any further questions about taking this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You should immediatelystop taking this medicine and contact your doctor or go to the emergency department of the nearest hospital if you experience:
Very common(occurring in more than 1 in 10 people):
Common(occurring in less than 1 in 10 people):
Uncommon(occurring in less than 1 in 100 people):
Frequency not known(frequency cannot be estimated from the available data):
If you experience any side effects, including any not listed in this leaflet, please tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C, 02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
There are no special precautions for storage.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Markings on the blister: Lot - batch number, EXP - expiry date.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Actimodan 100 mg is a white or almost white uncoated tablet with the markings "41" on one side and "J" on the other, measuring 12.6 mm × 5.5 mm.
The packaging of the medicine is blisters in a cardboard box. The packaging contains 30 or 100 tablets.
Actimodan 200 mg is a white or almost white uncoated tablet with the markings "4" and "2" separated by a dividing line on one side and "J" on the other, measuring 16.0 mm × 7.0 mm.
The tablet can be divided into equal doses.
The packaging of the medicine is blisters in a cardboard box. The packaging contains 30 or 100 tablets.
Not all pack sizes may be marketed.
Aflofarm Farmacja Polska Sp. z o.o.
Partyzancka 133/151
95-200 Pabianice
Phone: +48 (42) 22-53-100
APL Swift Services (Malta) Ltd,
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.